

Pulmonary Drug Delivery Systems: Technologies and Global Markets

<https://marketpublishers.com/r/PD4BA9ACF32EN.html>

Date: November 2022

Pages: 148

Price: US\$ 5,500.00 (Single User License)

ID: PD4BA9ACF32EN

Abstracts

Report Scope:

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.

In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.

The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.

Report Includes:

44 tables

A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems

Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027

Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region

Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs

In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market

Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials

Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market

Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies

Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Descriptive company profiles of the market leading players, including Abbott, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Lupin and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 What's New in This Update?
- 1.4 Scope of Report
- 1.5 Information Sources
 - 1.5.1 Secondary Research
 - 1.5.2 Primary Research
- 1.6 Methodology
- 1.7 Geographic Breakdown
- 1.8 Analyst's Credentials
- 1.9 BCC Custom Research
- 1.10 Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND

- 3.1 Market Definition and Overview
 - 3.1.1 Mechanism of Action
 - 3.1.2 Advantages
 - 3.1.3 Limitations/Challenges
- 3.2 Pulmonary Conditions and Therapies
 - 3.2.1 Introduction to the Respiratory System
- 3.3 Market Drivers and Trends
 - 3.3.1 Improved Patient Compliance and Ease of Use
 - 3.3.2 Cost Pressures on Countries
 - 3.3.3 Rising Incidence of Asthma
 - 3.3.4 Causes
 - 3.3.5 Reducing the Burden of Asthma
- 3.4 Market Restraints
 - 3.4.1 Competition from Generics on the Rise
- 3.5 Market Opportunities
 - 3.5.1 Introduction of Smart Nebulizers
- 3.6 Regulation and Legislation
 - 3.6.1 U.S.

CHAPTER 4 MARKET BREAKDOWN BY PULMONARY DRUG DELIVERY SYSTEMS

- 4.1 Overview of Inhalation Techniques
- 4.2 Dry Powder Inhalers (DPIs)
 - 4.2.1 Overview
 - 4.2.2 Marketed Products
- 4.3 Metered Dose Inhalers (MDIs)
 - 4.3.1 Overview
 - 4.3.2 Marketed Products
- 4.4 Nebulizers
 - 4.4.1 Overview
 - 4.4.2 Marketed Products Overview by Manufacturer

CHAPTER 5 COVID-19 IMPACT

- 5.1 Overview
- 5.2 COVID-19 Crisis
- 5.3 Impact on Market for Pulmonary Drug Delivery Systems
- 5.4 Current Outlook

CHAPTER 6 PULMONARY DRUG DELIVERY SYSTEMS IN USE

- 6.1 Therapeutic Agents Administered via Inhalation
 - 6.1.1 Steroids
 - 6.1.2 Bronchodilators

CHAPTER 7 MARKET BREAKDOWN BY DISEASE AREA

- 7.1 Introduction
- 7.2 Asthma
 - 7.2.1 Asthma Attacks
 - 7.2.2 Asthma and Obesity
 - 7.2.3 Mortality
 - 7.2.4 Disease Classification
 - 7.2.5 Diagnosis
 - 7.2.6 Treatment and Therapies
 - 7.2.7 Market Size and Forecasts

7.3 Chronic Obstructive Pulmonary Disease (COPD)

7.3.1 Diagnosis

7.3.2 Treatment and Therapies

7.3.3 Market Size and Forecasts

7.4 Other Diseases

7.4.1 Market Size and Forecasts

CHAPTER 8 MARKET BREAKDOWN BY REGION

8.1 North America

8.1.1 U.S.

8.1.2 Canada

8.1.3 Mexico

8.2 Europe

8.2.1 Germany

8.2.2 U.K.

8.2.3 France

8.2.4 Italy

8.2.5 Spain

8.2.6 Rest of Europe

8.3 Asia-Pacific

8.3.1 China

8.3.2 Japan

8.3.3 India

8.3.4 South Korea

8.3.5 Rest of Asia-Pacific

8.4 Rest of the World

8.5 South America

CHAPTER 9 PATENT ANALYSIS

9.1 Overview

CHAPTER 10 COMPANY PROFILES

3M

ABBOTT LABORATORIES

ASTRAZENECA

BOEHRINGER INGELHEIM GMBH

CIPLA
DR. REDDY'S LABORATORIES LTD.
GLAXOSMITHKLINE PLC
PHILIPS RESPIRONICS
LUPIN
MYLAN N.V.
MERCK KGAA
NOVARTIS AG
OMRON CORP.
PFIZER INC.
PULMATRIX INC.
TEVA PHARMACEUTICALS INDUSTRIES LTD.

CHAPTER 11 APPENDIX: ABBREVIATIONS

List Of Tables

LIST OF TABLES

Summary Table A: Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027

Summary Table B: Global Market for Pulmonary Drug Delivery Systems, by Region, Through 2027

Table 1: Key Products Going Off-Patent, 2020-2030

Table 2: Inhaler Device Characteristics

Table 3: Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027

Table 4: Capsule-based Inhaler Devices

Table 5: Blister-based Inhaler Devices

Table 6: Reservoir/Cartridge-based Inhaler Devices

Table 7: MDIs, HFA Propellant

Table 8: MDIs, Anti-Inflammatory Medicine

Table 9: MDIs, Combination Medicine

Table 10: Commonly Used MDIs

Table 11: Comparison of Nebulizers

Table 12: Marketed Nebulizers by Manufacturer

Table 13: Total Number of COVID-19 Confirmed Cases and Deaths, by Region, June 2022

Table 14: COVID-19 Confirmed Cases and Deaths Globally, by Country, June 20, 2022

Table 15: Inhaled Steroids

Table 16: Inhaled Corticosteroids

Table 17: Inhaled Corticosteroids, Combination Inhalers

Table 18: Short-Acting Inhaled Beta-Agonist (SABA) Bronchodilators

Table 19: Short-Acting Inhaled Muscarinic Antagonist (SAMA) and SABA Combination Bronchodilators

Table 20: Long-Acting Inhaled Beta-2 Agonists (LABA) Bronchodilators

Table 21: Long-Acting Inhaled Muscarinic Antagonists (LAMA) Bronchodilators

Table 22: LABA and LAMA Combination Bronchodilators

Table 23: Global Asthma Market, Through 2027

Table 24: Leading Causes of Death Worldwide, 2020

Table 25: Global COPD Market, Through 2027

Table 26: Global Market for Other Pulmonary Diseases, Through 2022

Table 27: Prevalence of Asthma, by Race and Ethnicity in Americans

Table 28: European Self-Reported Asthma, 2020

Table 29: European Self-Reported COPD, 2020

Table 30: Leading Causes of Death in Australia, 2020 and 2021

Table 31: Key Patents, Pulmonary Drug Delivery Systems

Table 32: 3M: Key Developments

Table 33: Abbott: Product Portfolio by Business Segment, 2021

Table 34: Abbott: Key Developments

Table 35: AstraZeneca PLC: Key Developments

Table 36: Royal Philips: List of Subsidiaries

Table 37: Philips Health: Business Segments

Table 38: Lupin: Key Developments

Table 39: Novartis AG: Key Developments

Table 40: Pfizer Inc.: Key Developments

Table 41: Teva: Key Developments

Table 42: Abbreviations Used in Pulmonary Drug Delivery Systems

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027

Figure 1: Smoking in Adults, by Region, 2020

Figure 2: Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027

Figure 3: Non-Communicable Disease Mortality Share, by Cause of Death, 2021

Figure 4: Global Asthma Market, 2019-2027

Figure 5: Global COPD Market, 2019-2027

Figure 6: Global Market for Other Pulmonary Diseases, 2019-2027

Figure 7: North American Pulmonary Drug Delivery Systems Market, 2019-2027

Figure 8: Health Issues in the Mexican Population, Proportional Mortality, 2020

Figure 9: Annual Mortality Rate for Asthma, by Country, 2020

Figure 10: European Pulmonary Drug Delivery Systems Market, 2019-2027

Figure 11: U.K. Mortality, by Disease 2021

Figure 12: Leading Causes of Death in Italy, Percentage Change, 2020

Figure 13: Leading Causes of Death in Rest of Europe Region, 2021

Figure 14: Asia-Pacific Pulmonary Drug Delivery Systems Market, 2019-2027

Figure 15: Annual Mortality Rates in Middle East and Africa, by Disease, 2020

Figure 16: Rest of the World Pulmonary Drug Delivery Systems Market, 2019-2027

Figure 17: Abbott: Annual Revenue, 2018-2021

Figure 18: Abbott: Revenue Share, by Segment, 2021

Figure 19: AstraZeneca PLC: Annual Revenue, 2018-2020

Figure 20: AstraZeneca PLC: Revenue Share, by Therapy Areas, 2020

Figure 21: Dr. Reddy's Laboratories Ltd.: Annual Revenue, 2018-2020

Figure 22: Dr. Reddy's Laboratories Ltd.: Revenue Share, by Business Segment, 2020

Figure 23: GlaxoSmithKline PLC: Annual Revenue, 2018-2020

Figure 24: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020

Figure 25: Lupin: Annual Revenue, 2018-2020

Figure 26: Merck KGaA: Annual Revenue, 2018-2020

Figure 27: Merck KGaA: Revenue Share, by Business Segment, 2020

Figure 28: Novartis AG: Annual Revenue, 2018-2020

Figure 29: Novartis AG: Revenue Share, by Division, 2020

Figure 30: Pfizer Inc.: Annual Revenue, 2018-2020

Figure 31: Teva: Annual Revenue, 2018-2020

I would like to order

Product name: Pulmonary Drug Delivery Systems: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/PD4BA9ACF32EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD4BA9ACF32EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970